Bionano Genomics (BNGO) grants 5,000 options to officer
Rhea-AI Filing Summary
Bionano Genomics, Inc. reported that Principal Accounting Officer Mark Adamchak received a grant of 5,000 stock options to buy common stock at an exercise price of $1.12 per share, vesting 50% on each of the first and second anniversaries of the vesting commencement date and expiring on August 2, 2036. This Form 4 replaces an erroneously filed initial Form 3.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Adamchak Mark
Role
Principal Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 5,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,000 shares (Direct)
Footnotes (2)
- F1. The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date.
- F2. The initial Form 3 filed on August 5, 2026 was erroneously filed. This Form 4 replaces the Form 3 filed.
Key Figures
Stock options granted: 5,000 options
Exercise price: $1.1200 per share
Underlying common shares: 5,000 shares
+3 more
6 metrics
Stock options granted
5,000 options
Grant to Principal Accounting Officer Mark Adamchak on 2026-08-03
Exercise price
$1.1200 per share
Conversion or exercise price of the granted stock options
Underlying common shares
5,000 shares
Common Stock issuable upon exercise of the options
Options after transaction
5,000 options
Total derivative securities held directly following this grant
Option expiration date
2036-08-02
Expiration date of the stock option award
Vesting schedule
50% per year over 2 years
50% vests on each of the first and second anniversaries of vesting commencement
Key Terms
Stock Option (Right to Buy), vesting commencement date, Continuous Service, 2018 Plan
4 terms
Stock Option (Right to Buy) financial
"The security title is "Stock Option (Right to Buy)" for this grant"
vesting commencement date financial
"Vests 50% on each of the first and second anniversaries of the vesting commencement date"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
Continuous Service financial
"Vesting is subject to the Reporting Person's Continuous Service under the 2018 Plan"
2018 Plan financial
"Continuous Service is defined in the Company's 2018 Plan referenced in the footnote"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stock option grant did Bionano Genomics (BNGO) report for Mark Adamchak?
Bionano Genomics reported that Principal Accounting Officer Mark Adamchak received 5,000 stock options with a $1.12 exercise price. The options cover 5,000 shares of common stock and reflect his direct derivative holdings from this award after the grant, according to the Form 4.
How do Mark Adamchak’s new Bionano Genomics (BNGO) options vest?
The 5,000 options granted to Mark Adamchak vest 50% on the first anniversary and 50% on the second anniversary of the vesting commencement date, provided he remains in Continuous Service under Bionano Genomics’ 2018 Plan through each applicable vesting date.
What are the exercise price and expiration date of Adamchak’s Bionano Genomics (BNGO) options?
The granted options have an exercise price of $1.12 per share and an expiration date of 2036-08-02. These terms define the price at which he may buy common shares and the last date on which the options can be exercised.
Does this Bionano Genomics (BNGO) Form 4 indicate a Rule 10b5-1 trading plan?
The Form 4’s Rule 10b5-1 checkbox is not checked, and the footnotes do not reference any trading plan. This indicates the reported stock option grant was not disclosed as being made under a Rule 10b5-1 pre-arranged trading arrangement.
Why does the Bionano Genomics (BNGO) Form 4 mention an earlier Form 3 filing?
A footnote explains that an initial Form 3 filed on August 5, 2026 was erroneously filed. The current Form 4 states that it replaces that Form 3, clarifying Adamchak’s reportable positions through this corrected insider filing.